Inmed pharmaceuticals (inm): generating commercial sales of cbc and cbt

London, uk / accesswire / february 16, 2022 / inmed pharmaceuticals' (inm's) q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3m, all cannabichromene (cbc). as of january, it also began selling cannabicitran (cbt) to the health and wellness market.
INM Ratings Summary
INM Quant Ranking